Transplantation and Liver Surgery, Abdominal Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland,
Department of Pathology, University of Helsinki and HUSLAB, Helsinki University Hospital, Helsinki, Finland.
Oncology. 2021;99(3):144-160. doi: 10.1159/000510609. Epub 2020 Oct 7.
The liver metastases of colorectal cancer (CRC) can be surgically treated in selected cases, with continuously improving results. Matrix metalloproteinases (MMPs) contribute to cancer invasion by degrading the extracellular matrix, and elevated levels of MMP-2, MMP-8, and MMP-9 have been detected in several malignancies. Myeloperoxidase (MPO) is a mediator of tissue damage that can oxidatively activate latent MMPs. We evaluated the prognostic value of MMP-2, MMP-8, and MMP-9 in tissue samples of primary tumors and liver metastases and the pre- and postoperative serum levels of MMP-8, MMP-9, and MPO in CRC patients undergoing liver resection.
Tissue and serum samples were obtained from 111 patients who had primary colorectal tumors and their liver metastases surgically treated at the Helsinki University Hospital between 1988 and 2007. Tissue expression of MMP-2, MMP-8, and MMP-9 in primary tumors and liver metastases was evaluated by immunohistochemistry. Pre- and postoperative serum concentrations of MMP-8, MMP-9, and MPO were determined using a time-resolved immunofluorometric assay or commercially available enzyme-linked immunosorbent assay kits. Clinical data were retrieved from patient records and the Central Statistical Office of Finland. Associations with disease-free survival (DFS) and overall survival (OS) were estimated using Cox regression analysis and the Kaplan-Meier method.
High expression of MMP-9 in colorectal tumor tissue was associated with better DFS (p = 0.010), and high preoperative MPO in serum with improved DFS and OS (p < 0.001 and p = 0.014, respectively). The prognostic significance varied according to gender, age, and the synchronicity of liver metastases.
Low preoperative MPO in serum might identify patients at high risk of recurrence and death after resection of colorectal liver metastases. Elevated preoperative MPO and high expression of MMP-9 in colorectal tumor tissue indicate an improved prognosis. The use of these biomarkers should be adjusted according to clinical characteristics.
在选定的病例中,结直肠癌(CRC)的肝转移可以通过手术治疗,且治疗效果不断改善。基质金属蛋白酶(MMPs)通过降解细胞外基质促进癌症侵袭,在几种恶性肿瘤中已检测到 MMP-2、MMP-8 和 MMP-9 的水平升高。髓过氧化物酶(MPO)是一种介导组织损伤的物质,可以氧化激活潜伏的 MMPs。我们评估了 MMP-2、MMP-8 和 MMP-9 在原发肿瘤和肝转移组织样本中的预后价值,以及接受肝切除术的 CRC 患者的 MMP-8、MMP-9 和 MPO 的术前和术后血清水平。
我们从 1988 年至 2007 年在赫尔辛基大学医院接受手术治疗的原发性结直肠癌患者及其肝转移灶中获得了组织和血清样本。通过免疫组织化学评估 MMP-2、MMP-8 和 MMP-9 在原发肿瘤和肝转移中的组织表达。使用时间分辨免疫荧光测定法或市售酶联免疫吸附测定试剂盒测定 MMP-8、MMP-9 和 MPO 的术前和术后血清浓度。从患者记录和芬兰中央统计局检索临床数据。使用 Cox 回归分析和 Kaplan-Meier 方法评估与无病生存(DFS)和总生存(OS)的相关性。
结直肠肿瘤组织中 MMP-9 的高表达与更好的 DFS 相关(p = 0.010),术前高 MPO 与改善的 DFS 和 OS 相关(p < 0.001 和 p = 0.014)。预后意义因性别、年龄和肝转移的同步性而异。
血清中低术前 MPO 可能会识别出接受结直肠癌肝转移切除术后复发和死亡风险高的患者。术前高 MPO 和结直肠肿瘤组织中 MMP-9 的高表达表明预后改善。这些生物标志物的使用应根据临床特征进行调整。